The current price of SKIN is $10.35 — it has decreased by 6.33% since the previous close. Data as of Nov 5, 2026.
SKIN is up 0.88% over the past week, down 11.69% over the past month and down 59.88% over the past year. The price is below its 200-day moving average of $16.43.
Analysts' average 12-month price target for SKIN is $8.50, which implies 17.87% downside from the current price. Individual estimates range from $2.00 to $11.00.
Of the 9 analysts covering SkinHealth Systems Inc., 1 rates it a buy, 6 rate it a hold and 2 rate it a strong sell. The overall consensus is neutral. Analyst ratings are opinions and do not guarantee future performance.
SkinHealth Systems Inc. has a market capitalization of $67.35M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, SkinHealth Systems Inc. posted a loss of $0.14 per share against an estimate of -$1.33, beating expectations by 89.47%. Upcoming reports are listed in the earnings calendar.
SkinHealth Systems Inc. reported revenue of $69.2M in its most recent quarter, which has decreased by 2.12% compared with the same quarter a year earlier. Analysts had expected $67.97M.
SkinHealth Systems Inc. has not paid any dividends over the past year.
In the latest trading session SKIN moved between $10.23 and $11.10, a range of 8.38% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of SkinHealth Systems Inc. shows a sell rating today and a sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for SkinHealth Systems Inc. is sell. Technical ratings are indicators, not investment advice.
Over the past 52 weeks SKIN has traded between $9.68 and $34.80. The current price is 70.26% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.